PNC Financial Services Group’s Taysha Gene Therapies TSHA Stock Holding History

PNC Financial Services Group’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.13K	Hold	1,053	–	–	﹤0.01%	4500
2026 Q2	$7.17K	Buy	1,053 +10	+1%	+$59	﹤0.01%	4243
2026 Q1	$4.66K	Sell	1,043 -11	-1%	-$51	﹤0.01%	4304
2025 Q4	$5.8K	Sell	1,054 -254	-19%	-$1.23K	﹤0.01%	4171
2025 Q3	$4.28K	Buy	1,308 +308	+31%	+$872	﹤0.01%	4268
2025 Q2	$2.31K	Hold	1,000	–	–	﹤0.01%	4373
2025 Q1	$1.39K	Hold	1,000	–	–	﹤0.01%	4447
2024 Q4	$1.73K	Hold	1,000	–	–	﹤0.01%	4317
2024 Q3	$2.01K	Hold	1,000	–	–	﹤0.01%	4289
2024 Q2	$2.24K	Buy	+1,000	New	+$2.91K	﹤0.01%	4226

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

PNC Financial Services Group's TSHA Position: Q3 2026 in Review

PNC Financial Services Group held its Taysha Gene Therapies (TSHA) position steady in Q3 2026 at 1,053 shares worth $5.13K. The position accounts for ﹤0.01% of the portfolio, ranked #4500.

PNC Financial Services Group first reported a position in TSHA in Q2 2024 and has held it in 10 quarters since. The position peaked at $7.17K in Q2 2026. 83 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

PNC Financial Services Group held 1,053 shares of Taysha Gene Therapies worth $5.13K as of Q3 2026.
PNC Financial Services Group left its Taysha Gene Therapies share count unchanged in Q3 2026.
Taysha Gene Therapies made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4500 holding.
PNC Financial Services Group first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 10 quarters since.
PNC Financial Services Group's Taysha Gene Therapies position peaked at $7.17K in Q2 2026.
83 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.